05 February 2015

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that the US Patent & Trademark Office (USPTO) has granted a three-year extension to the patent protection of MED2002, the Company's novel topical gel for the treatment of erectile dysfunction (ED).

The patent extension, until August 2028, reflects the time taken by the USPTO to process MED2002's initial patent application. MED2002 has patent protection in Europe until August 2025.

As announced in December 2014, a clinical study of MED2002 is expected to begin in Q1 2015 and to report later this year. Approximately 140 patients with ED will participate in the study, which will be a randomised, placebo-controlled, double blind, home use, cross-over design. The primary outcome of the study is statistically significant efficacy.

MED2002, which is expected to be a prescription-only product, has the potential to meet patient demand for an effective alternative to PDE5 inhibitors. A significant number of ED sufferers cannot be prescribed PDE5 inhibitors as they are contra-indicated with other medications that they take.

James Barder, Futura's Chief Executive, said: "We are very pleased to be awarded this three-year patent extension from the US Patent & Trademark Office for MED2002. This patent extension is potentially highly significant as, assuming US regulatory approval during 2018, it lengthens MED2002's commercial window by around 40 per cent in the world's largest pharmaceutical market."

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com